Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studies.

Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Reich SH, Prins TJ, Marakovits JT, Littlefield ES, Zhou R, Tikhe J, Ford CE, Wallace MB, Meador JW 3rd, Ferre RA, Brown EL, Binford SL, Harr JE, DeLisle DM, Worland ST.

J Med Chem. 1998 Jul 16;41(15):2806-18.

PMID:
9667970
2.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies.

Dragovich PS, Webber SE, Babine RE, Fuhrman SA, Patick AK, Matthews DA, Reich SH, Marakovits JT, Prins TJ, Zhou R, Tikhe J, Littlefield ES, Bleckman TM, Wallace MB, Little TL, Ford CE, Meador JW 3rd, Ferre RA, Brown EL, Binford SL, DeLisle DM, Worland ST.

J Med Chem. 1998 Jul 16;41(15):2819-34.

PMID:
9667971
3.

Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements.

Webber SE, Okano K, Little TL, Reich SH, Xin Y, Fuhrman SA, Matthews DA, Love RA, Hendrickson TF, Patick AK, Meador JW 3rd, Ferre RA, Brown EL, Ford CE, Binford SL, Worland ST.

J Med Chem. 1998 Jul 16;41(15):2786-805.

PMID:
9667969
4.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements.

Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Ford CE, Burke BJ, Rejto PA, Hendrickson TF, Tuntland T, Brown EL, Meador JW 3rd, Ferre RA, Harr JE, Kosa MB, Worland ST.

J Med Chem. 1999 Apr 8;42(7):1213-24.

PMID:
10197965
5.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 3. Structure-activity studies of ketomethylene-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Fuhrman SA, Patick AK, Matthews DA, Ford CE, Meador JW 3rd, Ferre RA, Worland ST.

J Med Chem. 1999 Apr 8;42(7):1203-12.

PMID:
10197964
6.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 8. Pharmacological optimization of orally bioavailable 2-pyridone-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Johnson TO, Hua Y, Luu HT, Sakata SK, Brown EL, Maldonado FC, Tuntland T, Lee CA, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Wu EY, Guo M, Borer BC, Nayyar NK, Moran T, Chen L, Rejto PA, Rose PW, Guzman MC, Dovalsantos EZ, Lee S, McGee K, Mohajeri M, Liese A, Tao J, Kosa MB, Liu B, Batugo MR, Gleeson JP, Wu ZP, Liu J, Meador JW 3rd, Ferre RA.

J Med Chem. 2003 Oct 9;46(21):4572-85.

PMID:
14521419
7.

Synthesis and evaluation of peptidyl Michael acceptors that inactivate human rhinovirus 3C protease and inhibit virus replication.

Kong JS, Venkatraman S, Furness K, Nimkar S, Shepherd TA, Wang QM, Aubé J, Hanzlik RP.

J Med Chem. 1998 Jul 2;41(14):2579-87.

PMID:
9651162
8.

Design, synthesis, and evaluation of nonpeptidic inhibitors of human rhinovirus 3C protease.

Webber SE, Tikhe J, Worland ST, Fuhrman SA, Hendrickson TF, Matthews DA, Love RA, Patick AK, Meador JW, Ferre RA, Brown EL, DeLisle DM, Ford CE, Binford SL.

J Med Chem. 1996 Dec 20;39(26):5072-82.

PMID:
8978838
9.

Structure-activity relationships of heteroaromatic esters as human rhinovirus 3C protease inhibitors.

Im I, Lee ES, Choi SJ, Lee JY, Kim YC.

Bioorg Med Chem Lett. 2009 Jul 1;19(13):3632-6. doi: 10.1016/j.bmcl.2009.04.114. Epub 2009 May 3.

PMID:
19464175
10.

Substituted benzamide inhibitors of human rhinovirus 3C protease: structure-based design, synthesis, and biological evaluation.

Reich SH, Johnson T, Wallace MB, Kephart SE, Fuhrman SA, Worland ST, Matthews DA, Hendrickson TF, Chan F, Meador J 3rd, Ferre RA, Brown EL, DeLisle DM, Patick AK, Binford SL, Ford CE.

J Med Chem. 2000 May 4;43(9):1670-83.

PMID:
10794684
11.

Structure-based design of ketone-containing, tripeptidyl human rhinovirus 3C protease inhibitors.

Dragovich PS, Zhou R, Webber SE, Prins TJ, Kwok AK, Okano K, Fuhrman SA, Zalman LS, Maldonado FC, Brown EL, Meador JW 3rd, Patick AK, Ford CE, Brothers MA, Binford SL, Matthews DA, Ferre RA, Worland ST.

Bioorg Med Chem Lett. 2000 Jan 3;10(1):45-8.

PMID:
10636240
12.

Non-covalent inhibitors of rhinovirus 3C protease.

Baxter A, Chambers M, Edfeldt F, Edman K, Freeman A, Johansson C, King S, Morley A, Petersen J, Rawlins P, Spadola L, Thong B, Van de Poël H, Williams N.

Bioorg Med Chem Lett. 2011 Jan 15;21(2):777-80. doi: 10.1016/j.bmcl.2010.11.110. Epub 2010 Nov 26.

PMID:
21183345
13.

Structure-based design of a parallel synthetic array directed toward the discovery of irreversible inhibitors of human rhinovirus 3C protease.

Johnson TO, Hua Y, Luu HT, Brown EL, Chan F, Chu SS, Dragovich PS, Eastman BW, Ferre RA, Fuhrman SA, Hendrickson TF, Maldonado FC, Matthews DA, Meador JW 3rd, Patick AK, Reich SH, Skalitzky DJ, Worland ST, Yang M, Zalman LS.

J Med Chem. 2002 May 9;45(10):2016-23.

PMID:
11985469
14.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. Part 7: structure-activity studies of bicyclic 2-pyridone-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Johnson TO, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Patick AK, Matthews DA, Hou X, Meador JW, Ferre RA, Worland ST.

Bioorg Med Chem Lett. 2002 Mar 11;12(5):733-8.

PMID:
11858991
15.

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 6. Structure-activity studies of orally bioavailable, 2-pyridone-containing peptidomimetics.

Dragovich PS, Prins TJ, Zhou R, Brown EL, Maldonado FC, Fuhrman SA, Zalman LS, Tuntland T, Lee CA, Patick AK, Matthews DA, Hendrickson TF, Kosa MB, Liu B, Batugo MR, Gleeson JP, Sakata SK, Chen L, Guzman MC, Meador JW 3rd, Ferre RA, Worland ST.

J Med Chem. 2002 Apr 11;45(8):1607-23.

PMID:
11931615
16.

Structure-based design and synthesis of macrocyclic human rhinovirus 3C protease inhibitors.

Namoto K, Sirockin F, Sellner H, Wiesmann C, Villard F, Moreau RJ, Valeur E, Paulding SC, Schleeger S, Schipp K, Loup J, Andrews L, Swale R, Robinson M, Farady CJ.

Bioorg Med Chem Lett. 2018 Mar 1;28(5):906-909. doi: 10.1016/j.bmcl.2018.01.064. Epub 2018 Feb 1.

PMID:
29433930
17.

In vitro antiviral activity and single-dose pharmacokinetics in humans of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease.

Patick AK, Brothers MA, Maldonado F, Binford S, Maldonado O, Fuhrman S, Petersen A, Smith GJ 3rd, Zalman LS, Burns-Naas LA, Tran JQ.

Antimicrob Agents Chemother. 2005 Jun;49(6):2267-75.

18.

New anti-viral drugs for the treatment of the common cold.

Maugeri C, Alisi MA, Apicella C, Cellai L, Dragone P, Fioravanzo E, Florio S, Furlotti G, Mangano G, Ombrato R, Luisi R, Pompei R, Rincicotti V, Russo V, Vitiello M, Cazzolla N.

Bioorg Med Chem. 2008 Mar 15;16(6):3091-107. doi: 10.1016/j.bmc.2007.12.030. Epub 2007 Dec 23.

PMID:
18248816
19.

NMR solution structures of the apo and peptide-inhibited human rhinovirus 3C protease (Serotype 14): structural and dynamic comparison.

Bjorndahl TC, Andrew LC, Semenchenko V, Wishart DS.

Biochemistry. 2007 Nov 13;46(45):12945-58. Epub 2007 Oct 18.

PMID:
17944485
20.

Design and structure-activity relationships of novel inhibitors of human rhinovirus 3C protease.

Kawatkar SP, Gagnon M, Hoesch V, Tiong-Yip C, Johnson K, Ek M, Nilsson E, Lister T, Olsson L, Patel J, Yu Q.

Bioorg Med Chem Lett. 2016 Jul 15;26(14):3248-3252. doi: 10.1016/j.bmcl.2016.05.066. Epub 2016 May 24.

PMID:
27265257

Supplemental Content

Support Center